VAM
CYT

Vazirani Asset Management’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Vazirani Asset Management’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,770
Closed -$44.8K – 26
2023
Q3 		$44.8K Sell
15,770
-140,365
-90% -$387K 0.07% 24
2023
Q2 		$406K Buy
+156,135
New +$327K 0.68% 16

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BI
Bulldog Investors Saddle Brook, New Jersey $445M AUM 2.55% 1-Year Est. Return

Vazirani Asset Management's CYT Position: Q4 2023 in Review

Vazirani Asset Management sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q4 2023, closing a stake of 15,770 shares — an estimated $44.8K sold.

Vazirani Asset Management first reported a position in CYT in Q2 2023 and held it in 2 quarters. The position peaked at $406K in Q2 2023. 38 funds tracked by Wall St. Rank hold CYT as of Q4 2023.

  • Vazirani Asset Management reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Vazirani Asset Management sold 15,770 Cyteir Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $44.8K.
  • Vazirani Asset Management first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2023 and held it in 2 quarters.
  • Vazirani Asset Management's Cyteir Therapeutics, Inc. Common Stock position peaked at $406K in Q2 2023.
  • 38 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Vazirani Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.